Trial Profile
Long-Term, Open-Label Safety and Efficacy Study of Atomoxetine Hydrochloride in Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 May 2016
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 16 May 2016 New trial record